胶质母细胞瘤中的热休克蛋白

Heat shock proteins in glioblastomas.

作者信息

Yang Isaac, Fang Shanna, Parsa Andrew T

机构信息

Department of Neurological Surgery, University of California at San Francisco, 505 Parnassus Avenue, Room M779, Campus 0112, San Francisco, CA 94143, USA.

出版信息

Neurosurg Clin N Am. 2010 Jan;21(1):111-23. doi: 10.1016/j.nec.2009.09.002.

DOI:10.1016/j.nec.2009.09.002

PMID:19944971

Abstract

Glioblastoma multiforme is the most common primary central nervous system tumor. The prognosis for these malignant brain tumors is poor, with a median survival of 14 months and a 5-year survival rate below 2%. Development of novel treatments is essential to improving survival and quality of life for these patients. Endogenous heat shock proteins have been implicated in mediation of both adaptive and innate immunity, and there is a rising interest in the use of this safe and multifaceted heat shock protein vaccine therapy as a promising treatment for human cancers, including glioblastoma multiforme.

摘要

多形性胶质母细胞瘤是最常见的原发性中枢神经系统肿瘤。这些恶性脑肿瘤的预后很差，中位生存期为14个月，5年生存率低于2%。开发新的治疗方法对于提高这些患者的生存率和生活质量至关重要。内源性热休克蛋白与适应性免疫和先天性免疫的调节均有关，并且人们越来越有兴趣将这种安全且具有多方面作用的热休克蛋白疫苗疗法作为包括多形性胶质母细胞瘤在内的人类癌症的一种有前景的治疗方法。